Elite Pharmaceuticals Inc (OTCPK:ELTP)
$ 0.38 +0.0062 (+1.66%) Market Cap: 408.11 Mil Enterprise Value: 384.13 Mil PE Ratio: 18.95 PB Ratio: 4.12 GF Score: 60/100

Q2 2025 Elite Pharmaceuticals Inc Earnings Call Transcript

Nov 15, 2024 / 04:30 PM GMT
Release Date Price: $0.5615 (+8.46%)

Key Points

Positve
  • Elite Pharmaceuticals Inc (ELTP) reported a 33% increase in quarterly revenues, reaching $18.9 million compared to the previous year.
  • Year-to-date revenues increased by 63%, totaling $37.7 million, indicating strong financial growth.
  • Operating income saw a significant rise, with an 81% increase for the quarter and a 108% increase for the six months year-to-date.
  • The company successfully launched new products, including methotrexate and codeine Apap, with more launches planned, indicating a robust product pipeline.
  • Elite Pharmaceuticals Inc (ELTP) achieved a positive cash flow of $4.6 million for the six months ended September 2024, a $7.5 million turnaround from the previous year.
Negative
  • The generic pharmaceuticals market remains highly competitive, which may impact pricing and sales variability.
  • There are ongoing challenges with API supply, affecting the launch schedule of certain products.
  • The company's liabilities increased by $11 million, primarily due to derivative liabilities related to warrants.
  • The approval of a central nervous system ANDA is pending, with potential delays if FDA requirements are not met.
  • The company faces uncertainties related to potential changes in administration policies, which could impact regulatory and market conditions.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ELTP.PK - Elite Pharmaceuticals Inc
Q2 2025 Elite Pharmaceuticals Inc Earnings Call
Nov 15, 2024 / 04:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning, ladies and gentlemen and welcome to the Elite Pharmaceuticals second quarter of fiscal year 2025 conference call.

At this time, all lines have been placed on a listen-only mode before management begins speaking, the conference has the following statement.

Elite would like to remind listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties that are subject to change at any time including but not limited to statements about elite's expectations regarding forward operating results, forward-looking statements are made pursuant to the safe harbor provisions of the federal securities laws and represent management's current expectations.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot